Article 46

EUROPEAN PATENT OFFICE

Information from the EPO

Decision of the President of the European Patent Office dated 24 April 2023 concerning the revision of WIPO Standard ST.26

In accordance with Article 1(5) of the decision dated 9 December 2021 on the filing of sequence listings1 and having regard to Article 10(2) EPC, Rules 30(1) and 163(3) EPC and Rule 13ter.1 PCT, considering that WIPO Standard ST.26 for the standardised presentation of nucleotide and amino acid sequences has been revised following its approval by the Committee on WIPO Standards (CWS) at the CWS's tenth session2 and that this new version 1.6 will enter into force on 1 July 2023, the President of the European Patent Office has decided as follows:

Article 1

Version of WIPO Standard ST.26 to be used for generating a standard-compliant sequence listing

(1) Under Article 1 of the above-mentioned decision dated 9 December 2021, the description must contain a sequence listing in XML format complying with WIPO Standard ST.26 if nucleotide or amino acid sequences are disclosed in a European patent application filed as from 1 July 2022.

(2) Sequence listings filed as from 1 July 2023 for European patent applications to which WIPO Standard ST.26 applies must comply with version 1.5 or 1.6 of that standard.

Article 2

Entry into force

This decision will enter into force on 1 July 2023.

Done at Munich, 24 April 2023

António CAMPINOS

President